Who is sponsoring NCT07198399?

NCT07198399 is sponsored by Auri Nutrition.

What drugs are being tested in NCT07198399?

Interventions in NCT07198399: Auri Super Mushroom Daily Gummies.

What condition does NCT07198399 study?

NCT07198399 studies Cognitive Decline, Focus Deficit.

Is NCT07198399 still recruiting?

NCT07198399 is currently completed. Last updated 30 September 2025.

Last reviewed 2025-09-30 · How we verify

NCT07198399

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Auri Super Mushroom Daily Gummies on Cognitive Health

Completed NA Last updated 30 September 2025

What this trial tests

NA trial testing Auri Super Mushroom Daily Gummies in Cognitive Decline in 35 participants. Completed in 1 August 2025.

Timeline

3 April 2025

Primary endpoint
1 August 2025

1 August 2025

Quick facts

Lead sponsor	Auri Nutrition
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	35
Start date	3 April 2025
Primary completion	1 August 2025
Estimated completion	1 August 2025
Sites	1 location across United States

Drugs / interventions tested

Auri Super Mushroom Daily Gummies

Conditions studied

Cognitive Decline — all drugs for Cognitive Decline →
Focus Deficit — all drugs for Focus Deficit →

Sponsor

Auri Nutrition

Who can join

30 and older, any sex, with Cognitive Decline or Focus Deficit. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-arm, open-label, virtual clinical trial evaluating the cognitive health effects of Auri Super Mushroom Daily Gummies in a population of 35 adult participants over 8 weeks. Participants will consume two gummies daily and complete validated cognitive testing and self-assessment questionnaires to assess changes in cognitive performance, energy, mood, memory, and overall well-being.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cognitive Decline

Currently open trials in the same condition.

NCT07220694 — Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairmen · NA · recruiting
NCT07394504 — Effects of Turning Based Dual Task Training on Balance and Mild Cognitive Impairment in Diabetic Peripheral Neuropathy · NA · recruiting
NCT07127965 — Exercise Adherence and Cognitive Decline: Phase 2 · NA · recruiting
NCT07151365 — Plant-based Diets and Healthy Aging · recruiting
NCT07399418 — TRIAD - Tracking Risk in Integrated Alzheimer's Diagnostics. · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07198399 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Auri Nutrition
Last refreshed: 30 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07198399.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing